Durect's Posimir: NDA Resubmission Raises Similar Safety Issues

How to score adverse events for Durect's surgical pain treatment could determine whether US FDA advisory committee recommends bupivacaine extended-release solution; agency questions whether Posimir's formulation may cause neurological adverse events.

Dissection forceps or hemostatic forceps passing in surgeon hand by team surgeons in surgery center for interventions with instruments in surgeon operation electrosurgery with thoracotomy microsurgery
Posimir is proposed for post-surgical local pain relief. • Source: Shutterstock

Durect Corp.'s second attempt to gain approval for a surgical pain treatment may hinge on a product characteristic that the US Food and Drug Administration identified as problematic during its first assessment of the application.

Bupivacaine extended-release solution, known as Posimir, is proposed for post-surgical analgesia to be accomplished by administration through instillation into the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers